CDEK
← All drugs Report issue

perflutren protein-type a microspheres

Trade name: Optison

Small moleculeapproved

Approved

Dec 31, 1997

Perflutren is a diagnostic drug that is used for the contrast enhancement during echocardiographic. It consists of lipid-coated microspheres filled with octafluoropropane gas. Ultrasound waves make the microspheres resonate and reflect a strong signal to an ultrasound machine. This results in a difference of density between gas-filled bubbles and blood around them and improves contrast of resulting images. Perflutren is used in patients with suboptimal echocardiograms to opacify the left ventricular chamber and improve the delineation of the heart borders. — NCATS

Clinical trial activity

88 trials · 60 clinical orgs · 2 marketing orgs

Phase 1
23
Phase 2
29
Phase 3
8
Phase 4
16

Earliest trial started Sep 1, 1985 (NCT00000140)

Timeline

1980s

  1. Jan 1, 1985

    Earliest Phase 3 Sponsor(trial)

1990s

  1. Dec 31, 1997

    Earliest FDA Approval

2000s

  1. Jul 31, 2001

    DuPont — First NDA Organization

  2. Jul 31, 2001

    Lantheus Medical Imaging — NDA Secondary Org

  3. Jul 31, 2001

    DuPont — NDA Organization

  4. Jan 1, 2002

    Earliest Phase 1 Sponsor(trial)

  5. Jan 1, 2004

    Lantheus Medical Imaging — Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

  • Unspecified targetOTHER

    Diagnostic agent

    Produced in lipid microspheres as a diagnostic agent

  • contrast mediumRadiopaque

    contrast medium radiopaque

Approval history

  • approvedDec 31, 1997

Chemistry & pharmacology

Loading structure…

SMILES

FC(F)(F)C(F)(F)C(F)(F)F
Mol. weight
188.0193 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • 1,1,1,2,2,3,3,3-octafluoropropane
  • 1,1,1,2,2,3,3,3-octafluoropropane
  • c3f8-gas
  • definity
  • definity
  • definity
  • dmp-115
  • dmp-115
  • fc 218
  • fc 218
  • freon 218
  • freon 218
  • fs069
  • fs069
  • fs069
  • fs 069
  • fs-069
  • fs-069
  • fs-069
  • luminity
  • luminity
  • luminity
  • luminity
  • luminity
  • mrx-115
  • mrx-115
  • mrx-115
  • octafluoropropane
  • octafluoropropane
  • octafluoropropane
  • octafluoropropane
  • octafluorpropan
  • octafluorpropan
  • octafluropropane
  • oktafluorpropan
  • oktafluorpropan
  • optison
  • optison
  • optison
  • optison
  • perfluoropropane
  • perfluoropropane
  • perfluoropropane
  • perfluoropropane
  • perfluoropropane
  • perfluoropropane-filled albumin microsphere solution
  • perflutren
  • perflutren
  • perflutren
  • perflutren
  • perflutren
  • perflutren
  • perflutren
  • perflutren
  • perflutren
  • perflutren protein-type a microspheres
  • perflutren protein-type a microspheres injectable suspension

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07225114Phase 2Dec 31, 2025National Cancer Institute (NCI), University of North Carolina at Chapel Hill
NCT07179328Phase 1Jun 4, 2025University of Toronto
NCT07193953Phase 1Apr 15, 2025Focused Ultrasound Foundation, University of Toronto
NCT06797193N/AMar 13, 2025Mayo Clinic
NCT06815627Phase 3Feb 28, 2025Cathay General Hospital, Chang Gung University, China Medical University, Mackay Medical College, National Taiwan University, Taipei Veteran General hospital, Trust Bio-sonics, Inc.
NCT06705075Phase 2Dec 1, 2024Thomas Jefferson University
NCT06571786Phase 2Sep 23, 2024Mayo Clinic, Thomas Jefferson University
NCT06185972Phase 2Feb 1, 2024Terry Fox Research Institute, University of Toronto
NCT06024772Phase 3Dec 31, 2023Thomas Jefferson University
NCT05764642Phase 2Aug 9, 2023Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT05613946Phase 1Dec 15, 2022Mayo Clinic
NCT05336786Phase 3Jun 15, 2022Thomas Jefferson University
NCT05620290Phase 1Jun 15, 2022Terry Fox Research Institute, University of Toronto
NCT05328167Phase 2Dec 14, 2021Thomas Jefferson University
NCT04715958Phase 2/Phase 3 (Phase 3)Dec 7, 2020Thomas Jefferson University
NCT04721886Early Phase 1 (Phase 1)Nov 24, 2020Thomas Jefferson University
NCT06171607Phase 1Nov 5, 2020National Cancer Institute (NCI), University of Southern California
NCT04118764N/AAug 6, 2020Columbia University, National Institute on Aging (NIA)
NCT05247541Phase 2/Phase 3 (Phase 3)Jul 1, 2020Lantheus Medical Imaging, Thomas Jefferson University
NCT04328766Phase 1Jun 1, 2020Daewoong Pharmaceutical Co. LTD.
Showing 20 of 88 trials
Page 1 / 5

Organizations

Research & Development (60)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Thomas Jefferson UniversityAcademic/Hospital161642012
Lantheus Medical ImagingFor profit13642004
National Cancer Institute (NCI)Government10042007
Mayo ClinicAcademic/Hospital8642004
University of North Carolina at Chapel HillAcademic/Hospital8832013
University of TorontoAcademic/Hospital6632009
General ElectricFor profit5432008
University of VirginiaAcademic/Hospital5522006
University of NebraskaAcademic/Hospital4322012
University of Southern CaliforniaAcademic/Hospital4422013
University of Texas at HoustonAcademic/Hospital3222005
Vanderbilt UniversityAcademic/Hospital3022007
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Government2022012
National Institute on Aging (NIA)Government2012012
National Institutes of Health (NIH)Government2022006
Taipei Veteran General hospitalGovernment2022019
Terry Fox Research InstituteAcademic/Hospital2022022
The University of Texas, DallasAcademic/Hospital2212010
Trust Bio-sonics, Inc.For profit2222019
University of Alabama, BirminghamAcademic/Hospital2222010
60 organizations
Page 1 / 3

Marketing (2)

OrganizationOrg typeRelationshipDate
DuPontFor profitNDAJul 31, 2001
Lantheus Medical ImagingFor profitNDA2Jul 31, 2001